首页 › 基金 › Affinity Asset Advisors, LLC › LXEO
Affinity Asset Advisors, LLC 对 LXEO 的持仓历史
LEXEO THERAPEUTICS INC · 医疗保健
Affinity Asset Advisors, LLC 在 Q3 2026 的 13F 申报中披露持有 LXEO(LEXEO THERAPEUTICS INC)7,245,611 股,市值约 US$24.5M,约占其申报组合的 1.14%,在其申报持仓中市值排名第 26 位。 Affinity Asset Advisors, LLC 最近 7 个申报季度中有 7 个季度披露了 LXEO 持仓,最早可追溯至 Q1 2025。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Affinity Asset Advisors, LLC 对 LXEO 的持仓演变
Affinity Asset Advisors, LLC 于 Q1 2025 首次披露 LXEO 持仓:1,480,881 股(约 US$5.1M)。 该持仓在 Q4 2025 达到峰值 3,200,000 股,市值约 US$31.8M。 在 7 次申报中,Affinity Asset Advisors, LLC 5 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 7,245,611 股、市值约 US$24.5M,环比增持 1,438,000 股。。 持仓曾出现大幅变动:Q2 2025 增持约 142% (随后一个季度股价上涨 65%)、Q1 2026 增持约 58% (随后一个季度股价下跌 19%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2025 | 1.48M | $5.14M | 新进 |
| Q2 2025 | 3.59M | $14.43M | 增持 |
| Q3 2025 | 3.87M | $25.70M | 增持 |
| Q4 2025 | 3.20M | $31.78M | 减持 |
| Q1 2026 | 5.05M | $28.99M | 增持 |
| Q2 2026 | 5.81M | $27.03M | 增持 |
| Q3 2026 | 7.25M | $24.49M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 LXEO 与 13F 数据
LXEO(LEXEO THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 37 只申报持有 LXEO,申报仓位最大的包括:MONTANOVA CAPITAL, LLC (US$29.7M), Frazier Life Sciences Management, L.P. (US$22.5M), Vestal Point Capital, LP (US$20.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 LXEO 的基金
- MONTANOVA CAPITAL, LLC 6.38M 股 · $29.72M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.82M 股 · $22.46M · Q2 2026
- Vestal Point Capital, LP 4.32M 股 · $20.11M · Q2 2026
- Paradigm Biocapital Advisors LP 4.18M 股 · $19.44M · Q2 2026
- 683 Capital Management, LLC 1.88M 股 · $8.73M · Q2 2026
- Avoro Capital Advisors LLC 1.49M 股 · $6.93M · Q2 2026
- Spruce Street Capital LP 928.59K 股 · $3.14M · Q3 2026
- Jones Hill Capital LP 593.74K 股 · $2.01M · Q3 2026
- DAFNA Capital Management LLC 377.06K 股 · $1.76M · Q2 2026
更多关于 Affinity Asset Advisors, LLC
常见问题
How long has Affinity Asset Advisors, LLC held LXEO?
Affinity Asset Advisors, LLC has disclosed LXEO holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Affinity Asset Advisors, LLC's current position in LXEO?
As of Q3 2026, Affinity Asset Advisors, LLC holds 7.25M shares of LXEO (LEXEO THERAPEUTICS INC), valued at $24.49M, representing 1.14% of its reported portfolio and ranking #26.
Has Affinity Asset Advisors, LLC been buying or selling LXEO?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in LXEO. The position peaked in Q4 2025 at 3.20M shares.
Which other funds hold LXEO?
Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.